Lumida
/ICUI
⌘K
ICU Medical Inc

ICU Medical Inc

ICUI
$157.51USD↓-2.87%-4.66 today

MARKET CAP

3.9B

P/E (TTM)

19.7x

FWD P/E

18.0x

DAY RANGE

$157 – $163

52W RANGE

$107
$163

AI Summary

Stalk
Buy NowHigh

In a Stage 2 Advancing environment with clear higher highs and higher lows, price is pulling back into rising EMAs that served as support during the corrective reset, offering a favorable entry into the ongoing uptrend. The active Parabola pattern underscores accelerating demand and trend strength, reinforced by expanding volume on rallies and contracting volume on pullbacks. Despite near-term overbought context, no exhaustion is evident, and structural support remains intact. Primary risks include a breakdown below the EMAs and resistance at recent highs that could stall upside.

  • ↑Q1 revenue $526M with 1% organic growth despite deconsolidation headwinds.
  • ↑FY2026 free cash flow guidance of ~$150M underscores strong cash generation.
  • ↓Tariffs expected to add $25–30M in FY25 expenses, squeezing gross margins.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

ICU Medical, Inc. (NASDAQ: ICUI) specializes in infusion therapy products, focusing on systems and consumables that enhance patient safety in healthcare environments. The company operates primarily in the medical technology sector, where it has established a significant foothold following the joint venture with Otsuka Pharmaceutical Factory. This collaboration is designed to strengthen its position in the IV solutions space, aligning with overarching themes of innovation and operational efficiency amidst regulatory challenges.

Bull says

  • ↑Q1 revenue $526M with 1% organic growth despite deconsolidation headwinds.
  • ↑FY2026 free cash flow guidance of ~$150M underscores strong cash generation.
  • ↑Gross margin improved to 41%, reflecting enhanced operational efficiency.
  • ↑Adjusted EPS rose to $1.97 from $1.72 YoY, showing resilience.
  • ↑High earnings yield and elevated book-to-price ratio suggest undervaluation.
  • ↑Recent FDA 510(k) clearances support a 10-year product platform foundation.

Bear says

  • ↓Tariffs expected to add $25–30M in FY25 expenses, squeezing gross margins.
  • ↓Q1 revenue declined 12% YoY, driven by IV solutions deconsolidation.
  • ↓Negative profitability and unfavorable revisions factors raise earnings risks.
  • ↓Intensifying competition from Baxter, Medtronic, and B. Braun could limit pricing power.
  • ↓Vital Care segment underperformance risks slower long-term revenue growth.
  • ↓Oil price sensitivity may elevate input costs and operational expenses.

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 06-14-2026neutral

Transcript signals

Bull points

  • Adjusted diluted earnings per share for the quarter was $1.72 compared to 96 cents last year.
  • Revenue for Q1 was $599 million for total company growth of 10% on a constant currency basis, or 8% reported, and was aided far less than Q4 2024 from IV Solutions as the national shortage ended. All three reporting segments had good year-over-year growth.
  • Adjusted EBITDA was $99 million, and adjusted EPS was $1.72. Gross margins were in line with our expectations, and cash generation was healthy.

Bear points

  • Based on the tariff policies in place today, we would anticipate the direct expense from tariffs in FY25 to be in the range of 25 to 30 million, the vast majority of which would be recognized in the back half of the year as these costs are captured in cost of goods sold and subject to our cap and roll process.
  • we would likely be at the low end of the range for adjusted EBITDA, adjusted EPS, and adjusted gross margin if additional offsets aren't identified and captured.
  • Given the recent activity, I'll talk at a high level on what we've been doing the last two years to ensure safety, compliance, and improve product quality for CAD and MedFusion. First, we stopped selling and established end of support dates for the oldest versions of both product families.
Read full transcript analysis ›